OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation

LONDON, May 17, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (“DED”) and ocular pain, is pleased to announce the pricing of the underwritten initial public offering (the "Offering”) of its American Depositary Shares ("ADSs") on the Nasdaq Capital Market. OKYO will issue 625,000 ADSs (representing 40,625,000 new ordinary shares of no par value (the "Ordinary Shares")) at a price of $4.00 per ADS raising gross proceeds of approximately $2,500,000 (before deducting underwriting discount, commissions and offering expenses). Each ADS offered represents 65 Ordinary Shares. In addition, OKYO has granted the underwriters a 45-day option to purchase up to an additional 93,750 ADSs on the same terms and conditions. All ADSs to be sold in the Offering will be offered by the Company.